Meningioma after immunomodulation for multiple sclerosis.
CIEM Multiple Sclerosis Research Center, Federal University of Minas Gerais, Belo Horizonte MG, Brazil.
Rodrigo Gonçalves Kleinpaul
RG
Vieira
Thiago Cardoso
TC
Vale
Cristiane Franklin
CF
Rocha
Carolina Reis
CR
Araújo
Marco Aurélio
MA
Lana-Peixoto
D000328:Adult; D057915:Drug Substitution / Q000009:adverse effects; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D008577:Meningeal Neoplasms / Q000139:chemically induced*; D008579:Meningioma / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects
D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a